Search
Casirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … [L23539] This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.
Piroctone
go.drugbank.com/drugs/DB15946InvestigationalRecently was shown, that piroctone olamine could induce apoptosis and possessed a significant in vivo effect against myeloma.[L34189] … Piroctone olamine is used in combination with other substances as a part of shampoo effectively reduced the amount of dandruff and, at the same time, provided hair conditioning advantages.
Troclosene
go.drugbank.com/drugs/DB15960InvestigationalCategories: Compounds used in a research, industrial, or household settingTriacetin
go.drugbank.com/drugs/DB16005InvestigationalCategories: Compounds used in a research, industrial, or household settingGW810781
go.drugbank.com/drugs/DB16032InvestigationalGW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).
JBPOS0101
go.drugbank.com/drugs/DB16034InvestigationalJBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
PF-06882961
go.drugbank.com/drugs/DB16043InvestigationalPF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
2'-Fucosyllactose
go.drugbank.com/drugs/DB16052Investigational2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Zetomipzomib
go.drugbank.com/drugs/DB16070InvestigationalZetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).